ClinicalTrials.gg
CompletedNCT06138795Updated Sep 9, 2025

A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants

A Phase 1 interventional study of AZD2389 and Placebo in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2025, 1 year 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 368 studies in Liver Diseases with a site in United States — 45 open to participants now, 59 under way, 5 of them phase 3. Liver Diseases · United States.

Enrollment
64th of 269
120 · median 48
Started
2023
with 18 others
Phase 1
62 of 368
4 open now
Registered
326th of 368
by date

Among the 368 studies in Liver Diseases with a site in United States, this one is the 64th largest by enrollment of the 269 interventional ones that give a count, is one of 19 that started in 2023, is one of 62 in phase 1, and was the 326th registered.

Liver Diseases

825 studies on the registry are indexed under Liver Diseases; 152 are open to participants now.

Browse Liver Diseases studies →

Open to participants now

45 of the 368 studies in Liver Diseases with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Liver Diseases studies recruiting now, 51 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 19 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 368 studies in Liver Diseases with a site in United States, or all of them as a file.
02

Study summary

This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD2389 following single and multiple dose administration (SAD/MAD) to healthy participants.

Read the detailed description

This is a Phase I, First In Human (FIH), randomized, single-blind, placebo-controlled, single and multiple ascending dose study in healthy male and/or female participants of non-childbearing potential including healthy participants of Chinese and Japanese ethnicity performed at a single center.

The study consists of 2 parts: Part A and Part B. Part A has been planned to be conducted with 78 participants and Part B has been planned to be conducted with 32 participants.

Each participant in Part A and Part B will be involved in the study for up to 8 weeks.

03

Conditions studied

  • Healthy Participants

Browse trials for

Keywords

  • Liver disease
  • Single ascending dose
  • Multiple ascending dose
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female (of non-) participants with suitable veins for cannulation or repeated venipuncture.
  • For the healthy Japanese cohorts (Parts A2 and B2): healthy participants are to be Japanese (e.g., natives of Japan or Japanese Americans), defined as having both parents and 4 grandparents who are Japanese. This includes healthy second and third generation participants of Japanese descent whose parents or grandparents are living in a country other than Japan.
  • For the healthy Chinese cohort (Part A3): healthy participants are to be Chinese defined as having both parents and 4 grandparents who are ethnically Chinese. This includes second and third generation Chinese whose parents or grandparents are living in a country other than China.

Exclusion criteria

Exclusion Criteria:

  • Any illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IMP.
  • Known or suspected history of alcohol or drug abuse and smokers.
  • Plasma donation within one month of the Screening Visit or any blood donation/blood loss > 500 mL during the 3 months prior to the Screening Visit.
  • History of coagulation or bleeding disorders or use of anti-/anti-coagulants during the 3 months prior to the Screening Visit, as judged by the investigator.
  • History of as judged by the investigator, to drugs with a similar chemical structure or class.
  • History of severe dermatological disorders, eg, bullous pemphigoid or Stevens-Johnson syndrome, or clinically significant new or healing wounds in areas of the body not always covered by clothing such as face, forearm, and lower leg, as judged by the investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Cohort 1: Part A1 - AZD2389 dose 1/placebo oral administration

    A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.

    Drug: AZD2389 · Drug: Placebo

  • Experimental
    Cohort 2: Part A1 - AZD2389 dose 2/placebo oral administration

    A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.

    Drug: AZD2389 · Drug: Placebo

  • Experimental
    Cohort 3: Part A1 - AZD2389 dose 3 /placebo oral administration

    A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.

    Drug: AZD2389 · Drug: Placebo

  • Experimental
    Cohort 4: Part A1 - AZD2389 dose 4 /placebo oral administration

    A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.

    Drug: AZD2389 · Drug: Placebo

  • Experimental
    Cohort 5: Part A1 - AZD2389 dose 5 /placebo oral administration

    A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.

    Drug: AZD2389 · Drug: Placebo

  • Experimental
    Cohort 6: Part A1 - AZD2389 dose 6 oral administration

    A total of 6 study participants will receive a single dose of AZD2389.

    Drug: AZD2389

  • Experimental
    Cohort 7: Part A2 - AZD2389 dose 7 /placebo oral administration

    A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.

    Drug: AZD2389 · Drug: Placebo

  • Experimental
    Cohort 8: Part A2 - AZD2389 dose 8 /placebo oral administration

    A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.

    Drug: AZD2389 · Drug: Placebo

  • Experimental
    Cohort 9: Part A2 - AZD2389 dose 9 /placebo oral administration

    A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.

    Drug: AZD2389 · Drug: Placebo

  • Experimental
    Cohort 10: Part A3 - AZD2389 dose 10 /placebo oral administration

    A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.

    Drug: AZD2389 · Drug: Placebo

  • Experimental
    Cohort 11: Part B1 - AZD2389 dose 11 /placebo oral administration

    A total of 6 study participants will receive multiple doses of AZD2389 and 2 will receive placebo.

    Drug: AZD2389 · Drug: Placebo

  • Experimental
    Cohort 12: Part B1 - AZD2389 dose 12 /placebo oral administration

    A total of 6 study participants will receive multiple doses of AZD2389 and 2 will receive placebo.

    Drug: AZD2389 · Drug: Placebo

  • Experimental
    Cohort 13: Part B1 - AZD2389 dose 13 /placebo oral administration

    A total of 6 study participants will receive multiple doses of AZD2389 and 2 will receive placebo.

    Drug: AZD2389 · Drug: Placebo

  • Experimental
    Cohort 14: Part B2- AZD2389 dose 14/placebo oral administration

    A total of 6 study participants will receive multiple doses of AZD2389 and 2 will receive placebo.

    Drug: AZD2389 · Drug: Placebo

Interventions

  • Participants will receive AZD2389 orally as a single ascending dose or multiple ascending dose.

  • DrugPlacebo

    Participants will receive placebo matching the AZD2389 dose orally as a single ascending dose or multiple ascending dose.

06

What researchers measure

Primary outcomes

  1. Part A (SAD): Number of participants with adverse events (AE) and serious adverse events (SAE)

    To assess the safety and tolerability of AZD2389 following oral administration of single ascending doses in healthy participants, including Japanese and Chinese participants.

    Time frame: Day ≤ -28 (Only SAE), Day -1 (Only SAE), Days 1 and 2, Day 8 Post-dose (± 1 day)

  2. Part B (MAD): Number of participants with AE and SAE

    To assess the safety and tolerability of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.

    Time frame: Day ≤ -28 (Only SAE), Day -1 (Only SAE), Days 1 to 12, Day 17 (± 1 day)

Secondary outcomes

  1. Part A (SAD): Plasma concentrations of AZD2389

    To characterize the plasma concentration of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.

    Time frame: Day 1 and Day 2

  2. Part A (SAD): Urine concentrations of AZD2389

    To characterize the urine concentration of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.

    Time frame: Day 1 and Day 2

  3. Part A (SAD): Terminal rate constant (λz)

    To characterize the λz of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.

    Time frame: Day 1 and Day 2

  4. Part A (SAD): Cumulative amount of unchanged drug excreted into urine from time t1 to time t2 [Ae(t1-t2)]

    To characterize the Ae(t1-t2) of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.

    Time frame: Day 1 and Day 2

  5. Part A (SAD): Area under plasma concentration time curve from zero to infinity (AUCinf)

    To characterize the AUCinf of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.

    Time frame: Day 1 and Day 2

  6. Part A (SAD): Dose normalized AUCinf (AUCinf/D)

    To characterize the AUCinf/D of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.

    Time frame: Day 1 and Day 2

  7. Part A (SAD): Area under concentration curve from time 0 to the last quantifiable concentration (AUClast)

    To characterize the AUClast of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.

    Time frame: Day 1 and Day 2

  8. Part A (SAD): Dose normalized AUClast (AUClast/D)

    To characterize the AUClast/D of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.

    Time frame: Day 1 and Day 2

  9. Part A (SAD): Apparent total body clearance of drug (CL/F)

    To characterize the CL/F of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.

    Time frame: Day 1 and Day 2

  10. Part A (SAD): Maximum observed plasma (peak) drug concentration (Cmax)

    To characterize the Cmax of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.

    Time frame: Day 1 and Day 2

  11. Part A (SAD): Dose normalized Cmax (Cmax/D)

    To characterize the Cmax/D of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.

    Time frame: Day 1 and Day 2

  12. Part A (SAD): Renal clearance (CLR)

    To characterize the CLR of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.

    Time frame: Day 1 and Day 2

  13. Part A (SAD): Individual and cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 [fe(t1-t2)]

    To characterize the fe(t1-t2) of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.

    Time frame: Day 1 and Day 2

  14. Part A (SAD): Mean residence time (MRTinf)

    To characterize the MRTinf of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.

    Time frame: Day 1 and Day 2

  15. Part A (SAD): Apparent terminal elimination half-life (t½λz)

    To characterize the t½λz of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.

    Time frame: Day 1 and Day 2

  16. Part A (SAD): Time of last quantifiable concentration (tlast)

    To characterize the tlast of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.

    Time frame: Day 1 and Day 2

  17. Part A (SAD): Time to reach peak or maximum observed concentration (tmax)

    To characterize the tmax of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.

    Time frame: Day 1 and Day 2

  18. Part A (SAD): Apparent volume of distribution based on the terminal phase (Vz/F)

    To characterize the Vz/F of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.

    Time frame: Day 1 and Day 2

  19. Part A (SAD): Change in PD biomarkers over time

    To characterize the percentage change in PD biomarkers over time compared to baseline of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.

    Time frame: Day 1 and Day 2

  20. Part B (MAD): Plasma concentrations of AZD2389

    To characterize the plasma concentration of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.

    Time frame: Day 1 to Day 12

  21. Part B (MAD): Urine concentrations of AZD2389

    To characterize the urine concentration of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.

    Time frame: Day 1 and Days 10 to 12

  22. Part B (MAD): Terminal rate constant (λz)

    To characterize the λz of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.

    Time frame: Day 1 to Day 12

  23. Part B (MAD): Cumulative amount of unchanged drug excreted into urine from time t1 to time t2 [Ae(t1-t2)]

    To characterize the Ae(t1-t2) of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.

    Time frame: Day 1 and Days 10 to 12

  24. Part B (MAD): Area under concentration curve from time 0 to the last quantifiable concentration (AUClast)

    To characterize the AUClast of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.

    Time frame: Day 1 to Day 12

  25. Part B (MAD): Area under the concentration-time curve in the dose interval (AUCtau)

    To characterize the AUCtau of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.

    Time frame: Day 1 to Day 12

  26. Part B (MAD): Dose normalized AUCtau (AUCtau/D)

    To characterize the AUCtau/D of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.

    Time frame: Day 1 to Day 12

  27. Part B (MAD): Dose normalized AUClast (AUClast/D)

    To characterize the AUClast/D of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.

    Time frame: Day 1 to Day 12

  28. Part B (MAD): Apparent total body clearance of drug (CL/F)

    To characterize the CL/F of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.

    Time frame: Day 1 and Days 10 to 12

  29. Part B (MAD): Renal clearance (CLR)

    To characterize the CLR of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.

    Time frame: Day 1 and Days 10 to 12

  30. Part B (MAD): Maximum observed plasma (peak) drug concentration (Cmax)

    To characterize the Cmax of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.

    Time frame: Day 1 to Day 12

  31. Part B (MAD): Dose normalized Cmax (Cmax/D)

    To characterize the Cmax/D of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.

    Time frame: Day 1 to Day 12

  32. Part B (MAD): Observed lowest concentration before the next dose is administered(Ctrough)

    To characterize the Ctrough of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.

    Time frame: Day 1 to Day 12

  33. Part B (MAD): Individual and cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 [fe(t1-t2)]

    To characterize the fe(t1-t2) of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.

    Time frame: Day 1 and Days 10 to 12

  34. Part B (MAD): Accumulation ratio for AUC (Rac AUC)

    To characterize the Rac AUC of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.

    Time frame: Day 1 to Day 12

  35. Part B (MAD): Accumulation ratio for Cmax (Rac Cmax)

    To characterize the Rac Cmax of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.

    Time frame: Day 1 to Day 12

  36. Part B (MAD): Time to reach peak or maximum observed concentration (tmax)

    To characterize the tmax of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.

    Time frame: Day 1 to Day 12

  37. Part B (MAD): Apparent terminal elimination half-life (t½λz)

    To characterize the t½λz of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.

    Time frame: Day 1 to Day 12

  38. Part B (MAD): Apparent volume of distribution based on the terminal phase (Vz/F)

    To characterize the Vz/F of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.

    Time frame: Day 1 to Day 12

  39. Part B (MAD): Change in PD biomarkers over time

    To characterize the percentage change in PD biomarkers over time compared to baseline of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.

    Time frame: Days 1, 2, 4, 8, and 10

07

Study locations

1 site
  • Research Site
    Glendale, California 91206, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Aug 2025, 21 months.

Of 48 industry-sponsored phase 1 interventional studies under Liver Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 21 months is above that.

Counting every sponsor, half of 53 studies reached it within 14 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2023
First posted
Nov 18, 2023
StartActual
Nov 20, 2023
Primary completionActual
Aug 24, 2025
CompletionActual
Aug 24, 2025
Last update
Sep 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06138795
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 18, 2023
Start date
Nov 20, 2023
Primary completion
Aug 24, 2025
Completion
Aug 24, 2025
Last update
Sep 9, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD2389

Start the discussion